WO2016197878A1 - Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof - Google Patents
Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof Download PDFInfo
- Publication number
- WO2016197878A1 WO2016197878A1 PCT/CN2016/084647 CN2016084647W WO2016197878A1 WO 2016197878 A1 WO2016197878 A1 WO 2016197878A1 CN 2016084647 W CN2016084647 W CN 2016084647W WO 2016197878 A1 WO2016197878 A1 WO 2016197878A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- parts
- herbs
- treatment
- menopausal syndrome
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 64
- 206010027304 Menopausal symptoms Diseases 0.000 title claims abstract description 46
- 238000011282 treatment Methods 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 235000008216 herbs Nutrition 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract 3
- 239000002775 capsule Substances 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 13
- 241000756943 Codonopsis Species 0.000 abstract description 12
- 241000628997 Flos Species 0.000 abstract description 12
- 210000000582 semen Anatomy 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 230000002950 deficient Effects 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 abstract 1
- 206010038743 Restlessness Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 34
- 230000000694 effects Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 210000002216 heart Anatomy 0.000 description 13
- 230000009471 action Effects 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 8
- 230000009245 menopause Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000002657 hormone replacement therapy Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 3
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 3
- 229960003147 reserpine Drugs 0.000 description 3
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229940034208 thyroxine Drugs 0.000 description 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960003290 cortisone acetate Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 2
- 229960003226 nikethamide Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000132446 Inula Species 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000745390 Lophatherum Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- -1 amyl pentobarbital sodium Chemical compound 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000008492 tangshen Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Definitions
- the present invention relates to a compound preparation of traditional Chinese medicine, in particular to a pharmaceutical composition for the treatment of Menopausal Syndrome and the preparation method thereof.
- Menopausal syndrome is a series of symptoms caused by dropping levels of estrogen. Because the body cannot adapt quickly during menopause, some women will experience more obvious symptoms, but in generally they do not need special treatments. As for the women having severe symptoms even their daily life and work are severely affected, they need to use traditional Chinese medicine to invigorate kidney and bring back to health. It is generally believed that during the menopause transition years, the changes in family and social environment can increase women’s physical and mental burdens so that they are more prone to experience menopausal syndrome or the existing symptoms would be aggravated. For some mentally unstable women, their menopausal syndrome and even moodiness are more apparent.
- menopausal syndrome is caused by sex physiological changes, the incidence is directly related to the level of personal experience and psychological burden.
- any physical discomfort is likely to cause more psychological changes, which lead to a variety of menopausal symptoms. Therefore, it is important to pay attention to the psychological adjustment.
- the present invention provides a pharmaceutical composition for the treatment of menopausal syndrome and its preparation method.
- the method is believed to be simple, safe and reliable, and suitable for industrial production.
- a pharmaceutical composition for the treatment of Menopausal Syndrome wherein the pharmaceutical composition is consisted of the following herbs in weight parts: 1-3 parts Ramulus Cinnamomi, 0.5-2 parts Rhizoma Zingiberis, 2-4 parts Fructus Schisandrae Chinensis, 2-4 parts Flos Inulae, 3.5-5 parts Herba Lophatheri, 2-4 parts Cortex Moutan Radicis, 0.5-2 parts Fructus Jujubae, 2-4 parts Semen Ziziphi Spinosae, 2-4 parts Fructus Corni, 2-4 parts Radix Rehmanniae Recens, 2-4 parts Radix Codonopsis, and 0.5-2 parts Fructus Gardeniae.
- the pharmaceutical composition for the treatment of Menopausal Syndrome of the present invention has a high degree of safety and ideal effects for ameliorating Menopausal Syndrome. It is believed that the pharmaceutical composition resolves one or more of the technical problems in prior hormone replacement therapy, such as heavy loads on the liver and increasing probability of the incidence of endometrial cancer, breast cancer, thrombotic diseases and cholelithiasis.
- Ramulus Cinnamomi is also known as cassia twig or cinnamon twig. Quality: Pachet, Sweet, Warm. Meridians: Heart, Lung, Bladder. Actions: Induces sweating, warms and unblocks Meridian channels, reinforces yang transforming qi, and suppresses qi from rushing upwards.
- Rhizoma Zingiberis is also known as dried ginger. Quality: Pachet, Hot. Meridians: Spleen, Stomach, Kidney, Heart, Lung. Actions: Warms the spleen and stomach, restores damaged yang, warms the lung to transform thin mucus, warms and unblocks channels.
- Fructus Schisandrae Chinensis is also known as Chinese magnoliavine fruit. Quality: Sour, Sweet, Warm. Meridians: Lung, Heart, Kidney. Actions: Induces astringency, benefits qi for promoting fluid production, nourishes the kidneys and calms the hearts.
- Flos Inulae is also known as inula flower. Quality: Bitter, Purgit, Salty, slightly Warm. Meridians: Lung, Spleen, Stomach, Large Intestine. Actions: descends qi, dissipates phlegm, activates water, arrests vomitting.
- Herba Lophatheri is also known as lophatherum herb. Quality: Sweet, Bland, Cold. Meridians: Heart, Stomach, Small Intestine. Actions: clears hear-fire, clears annoyance and quenches thirst, increases urine and removes stone.
- Cortex Moutan Radicis is also known as tree peony root bark. Quality: Bitter, Pachet, slightly Cold. Meridians: Heart, Liver, Kidney. Actions: clears heat and cools blood, promotes blood circulation and removes blood stasis.
- Fructus Jujubae is also known as Chinese date. Quality: Sweet, Warm. Meridians: Spleed, Stomach, Heart. Actions: invigorates spleen and replenishes qi, nourishes blood and tranquilizes mind.
- Semen Ziziphi Spinosae is also known as spine date seed. Quality: Sweet, Sour, Neutral. Meridians: Liver, Bladder, Heart. Actions: invigorates heart and liver, calms heart and tranquilizes mind, astringes sweat, promotes fluid production.
- Fructus Corni is also known as asiatic cornelian cherry fruit. Quality: Sour, Astringent, slightly Warm. Meridians: Liver, Kidney. Actions: invigorates liver and kidney, astringes for relieving desertion.
- Radix Rehmanniae Recens is also known as unprocessed rehmannia root. Quality: Sweet, Cold. Meridians: Heart, Liver, Kidney. Actions: clears heat and cools blood, nourishes Yin and promotes fluid production.
- Radix Codonopsis is also known as tangshen. Quality: Sweet, Neutral. Meridians: Spleen, Lung. Actions: invigorates spleen and benefits lung, nourishes blood and promotes fluid production.
- Fructus Gardeniae is also known as cape jasmine fruit. Quality: Bitter, Cold. Meridians: Heart, Lung, Sanjiao. Actions: clears heat-fire and arrests annoyance, clears heat and promotes diuresis, cools blood and removes toxin.
- the pharmaceutical composition is consisted of the following herbs in weight ratios: 1-2.5 parts Ramulus Cinnamomi, 0.5-1.5 parts Rhizoma Zingiberis, 2-3.5 parts Fructus Schisandrae Chinensis, 2-3.5 parts Flos Inulae, 3.5-4.8 parts Herba Lophatheri, 2-3.5 parts Cortex Moutan Radicis, 0.5-1.5 parts Fructus Jujubae, 2-3.5 parts Semen Ziziphi Spinosae, 2-3.5 parts Fructus Corni, 2-3.5 parts Radix Rehmanniae Recens, 2-3.5 parts Radix Codonopsis, and 0.5-1.5 parts Fructus Gardeniae.
- the pharmaceutical composition per 30.5g is consisted of the following herbs in weight: Ramulus Cinnamomi 2g, Rhizoma Zingiberis1g, Fructus Schisandrae Chinensis 3g, Flos Inulae 3g, Herba Lophatheri 4.5g, Cortex Moutan Radicis 3g, Fructus Jujubae 1g, Semen Ziziphi Spinosae 3g, Fructus Corni 3g, Radix Rehmanniae Recens 3g, Radix Codonopsis 3g, and Fructus Gardeniae 1g.
- the pharmaceutical composition for the treatment of menopausal syndrome is manufactured in the form of oral liquid, tablets, capsules, pills, dropping pills, or granules.
- a method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
- the extracting solution is added with ethanol to a concentration of 50-80%, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.12-1.20 which is then dried to obtain the pharmaceutical composition for the treatment of menopausal syndrome, wherein the non-alcohol-soluble substances such as starch, protein, etc. are removed from the decocted extracting solution and forms an extracting solution having a concentration of alcohol by adding ethanol, and then a solid-liquid separation is performed by precipitation at room temperature or preferably lower temperature to improve the concentration and clarity of the alcohol extract and the product quality.
- the method comprises step D that the pharmaceutical composition is added with starch and homogenized before filling into capsules.
- the step B further comprises that after the filtrate is combined, the combined filtrate is concentrated into an extract with relative density of 1.20-1.25 at 60 °C.
- the step C comprises that the supernatant is concentrated into an extract relative density of 1.12-1.20 at 60 °C and spray-dried to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
- the present invention is a pharmaceutical composition prepared from traditional medicinal herbs of Ramulus Cinnamomi, Rhizoma Zingiberis, Fructus Schisandrae Chinensis, Flos Inulae, Herba Lophatheri, Cortex Moutan Radicis, Fructus Jujubae, Semen Ziziphi Spinosae, Fructus Corni, Radix Rehmanniae Recens, Radix Codonopsis, and Fructus Gardeniae.
- the pharmaceutical composition can supplement the liver and enriches the qi, nourishes the blood and calms the mind, clears internal heat, and relieves worries, which is especially applicable for women with menopausal syndrome that is induced by deficiency of Yin in their livers and kidneys. It is believed that the pharmaceutical composition for the treatment of menopausal syndrome consisted of the raw materials in such ratios offers a high degree of safety and is effective for improving the symptoms of menopause.
- the preparation method of the present invention is a simple operation, and is environmentally friendly, economic, efficient, non-toxic, and has the prospect of broad applications.
- a pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of pillors, in which the pharmaceutical composition is consisted of the following herbs in weight parts: 1 part Ramulus Cinnamomi, 0.5 part Rhizoma Zingiberis, 2 parts Fructus Schisandrae Chinensis, 2 parts Flos Inulae, 3.5 parts Herba Lophatheri, 2 parts Cortex Moutan Radicis, 0.5 parts Fructus Jujubae, 2 parts Semen Ziziphi Spinosae, 2 parts Fructus Corni, 2 parts Radix Rehmanniae Recens, 2 parts Radix Codonopsis, and 0.5 parts Fructus Gardeniae.
- the method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
- the extracting solution is added with ethanol to a concentration of 50%, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.12, and then blended and pelletized to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
- a pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of oral liquid, in which the pharmaceutical composition is consisted of the following herbs in weight parts: 3 part Ramulus Cinnamomi, 2 part Rhizoma Zingiberis, 4 parts Fructus Schisandrae Chinensis, 4 parts Flos Inulae, 5 parts Herba Lophatheri, 4 parts Cortex Moutan Radicis, 2 parts Fructus Jujubae, 4 parts Semen Ziziphi Spinosae, 4 parts Fructus Corni, 4 parts Radix Rehmanniae Recens, 4 parts Radix Codonopsis, and 2 parts Fructus Gardeniae.
- the method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
- the extracting solution is added with ethanol to a concentration of 80%, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.12 at 60 °C, and then batched and filled to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
- a pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of tablets, in which the pharmaceutical composition is consisted of the following herbs in weight parts: 2.5 part Ramulus Cinnamomi, 1.5 part Rhizoma Zingiberis, 3.5 parts Fructus Schisandrae Chinensis, 3.5 parts Flos Inulae, 4.8 parts Herba Lophatheri, 3.5 parts Cortex Moutan Radicis, 1.5 parts Fructus Jujubae, 3.5 parts Semen Ziziphi Spinosae, 3.5 parts Fructus Corni, 3.5 parts Radix Rehmanniae Recens, 3.5 parts Radix Codonopsis, and 1.5 parts Fructus Gardeniae.
- the method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
- the extracting solution is added with ethanol to a concentration of 60%, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.15 at 60 °C, and then spray dried, granulated and compressed to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
- a pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of capsules, in which the pharmaceutical composition is consisted of the following herbs in weight parts: 2 part Ramulus Cinnamomi, 1 part Rhizoma Zingiberis, 3 parts Fructus Schisandrae Chinensis, 3 parts Flos Inulae, 4.5 parts Herba Lophatheri, 3 parts Cortex Moutan Radicis, 1 parts Fructus Jujubae, 3 parts Semen Ziziphi Spinosae, 3 parts Fructus Corni, 3 parts Radix Rehmanniae Recens, 3 parts Radix Codonopsis, and 1 part Fructus Gardeniae.
- the method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
- the extracting solution is added with ethanol to a concentration of 80%, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.15 at 60 °C, and then spray dried; and
- a pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of granules, in which the pharmaceutical composition per 30.5g is consisted of the following herbs in weights: Ramulus Cinnamomi 2g, Rhizoma Zingiberis 1g, Fructus Schisandrae Chinensis 3g, Flos Inulae 3g, Herba Lophatheri 4.5g, Cortex Moutan Radicis 3g, Fructus Jujubae 1g, Semen Ziziphi Spinosae 3g, Fructus Corni 3g, Radix Rehmanniae Recens 3g, Radix Codonopsis 3g, and Fructus Gardeniae 1g.
- the method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
- the extracting solution is added with ethanol to a concentration of 80%, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.20 at 60 °C, and then dried and pelletized to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
- a pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of dripping pills, in which the pharmaceutical composition is consisted of the following herbs in weight parts: 2 part Ramulus Cinnamomi, 1 part Rhizoma Zingiberis, 3 parts Fructus Schisandrae Chinensis, 3 parts Flos Inulae, 4.5 parts Herba Lophatheri, 3 parts Cortex Moutan Radicis, 1 parts Fructus Jujubae, 3 parts Semen Ziziphi Spinosae, 3 parts Fructus Corni, 3 parts Radix Rehmanniae Recens, 3 parts Radix Codonopsis, and 1 part Fructus Gardeniae.
- the method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
- the extracting solution is added with ethanol to a concentration of 80%, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.20 at 60 °C, and then batched and made into pills to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
- ICR mice female, weight 18 ⁇ 22g
- a normal control group is fed with water at 0.2ml /10g per day; and the remaining three test groups are administered orally daily doses of the capsules at 2.0g /kg, 1.0 g /kg, and 0.5 g /kg respectively.
- mice are measured within 5 minutes by a Locomotor activity meter (XZ-4 type, from the Drug Institute of Chinese Academy) , and at 30 minutes after the 9 th administration, the mice are intraperitoneally injected with 50mg /kg of amyl pentobarbital sodium and their latent sleep time (latency) and sleep time are recorded.
- the mice are given an intraperitoneal dose of Nikethamide 350mg /kg, and their mortality rate caused by convulsions and seizures is observed. No seizures are calculated as 100 minutes.
- ICR mice 15-month-old, female, weigh 28 ⁇ 40g are divided into four groups according to drug administration protocols (the pharmaceutical composition capsules for the treatment of menopausal syndrome obtained from Example 4) .
- a normal control group is fed with water at 0.2ml /10g per day; and the remaining three test groups are administered orally daily doses of the capsules at 2.0g /kg, 1.0 g /kg, and 0.5 g /kg respectively. All groups of the mice are bred in a conventional manner in the laboratory for 20 days, and then start to be given the menopausal capsules or an equal volume of water.
- the independent activity numbers of mice are measured within 5 minutes.
- mice are intra-peritoneally injected with amphetamine at 10mg /kg and the independent activity numbers of mice are measured within 5 minutes after 10 minutes.
- the mice are sacrificed and their uterus, ovaries and adrenal glands are removed and weighed.
- ICR mice female, weigh 22 ⁇ 25g are divided into five groups according to drug administration protocols (the pharmaceutical composition capsules for the treatment of menopausal syndrome obtained from Example 4) .
- the first group is a control group that is fed with water at 0.2ml /10g per day; the second group is fed daily for consecutive 20 days with thyroxine 0.3 mg and reserpine 0.02mg.
- the remaining three groups are fed orally with thyroxine 0.3 mg and reserpine 0.02mg daily for 20 consecutive days, and concomitantly a daily dose of menopausal pharmaceutical composition at 2.0g /kg, 1.0 g /kg and 0.5 g /kg respectively.
- mice On the14th day, the independent activity numbers of mice are measured. On the 15 th day, the mice are given intra peritoneal injection of 5%Sheep erythrocytes at 0.2ml/mouse. On the 21 st day, a sample of blood from the femoral artery is collected, the blood serum is separated and the serum hemolysin level determined. The mouse spleen is removed by sterile technique and the lymphocyte transformation and NK cell killing rate are measured.
- mice The results in Table 3 show that the thyroxine and reserpine induced weight loss and development of fluffy yellow coat in mice and increased their activities. There was a significant Yin deficiency in symptoms.
- the menopausal capsules significantly increased body weight in mice and improved their appearance. There was also a significant decline in their independent activity nembers.
- Yin deficient mice showed significant decrease in their humoral and cellular immune functions.
- the menopause capsule significantly improved cell immune function (lymphocyte transformation) activity but had no significant impact on the specific humoral immune function (HC50) and NK cell activity of immune deficient mice.
- the 70 pcs ICR mice (female, weigh 22 ⁇ 24g) are divided into five groups according to drug administration protocols (the pharmaceutical composition capsules for the treatment of menopausal syndrome obtained from Example 4) .
- the first group is a control group that is fed with water 0.2ml /10g per day; the second group is injected every morning with cortisone acetate 1mg /mouse only for 7 days; the remaining three groups are given every morning intramuscular cortisone acetate 1mg /mouse only, while the amount of menopausal capsule administered orally every afternoon are 2.0g /kg, 1.0 g /kg, 0.5 g /kg respectively for 7 days.
- mice On the third day the mice are given by an intra peritoneal injection of 20%sheep erythrocytes 0.2ml /mouse.
- femoral arterial blood collected, thymus and spleen weighed; organ coefficient calculation, serum lectin and hemolysin level determined.
- mice The results in Table 4 show that the corticosteroids caused significant Yang deficiency symptoms in mice including significant weight loss, fluffy fur, reduced activity, hypothermia, unresponsiveness and so on.
- the menopausal capsule partially restored corticosteroid-induced weight loss and the general state of the animals was relatively good. Glucocorticoid led to a reduction in the weight of the immune organs in mice and significantly decreased their ability to produce specific antibodies.
- the menopausal capsules significantly restored the weight of the spleen and thymus in mice, their specific immune function was also restored.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Pharmaceutical composition for the treatment of menopausal syndrome and preparation method thereof, said composition consists of the following weight parts of herbs: Ramulus Cinnamomi 1-3, Rhizoma Zingiberis 0.5-2, Fructus Schisandrae Chinensis 2-4, Flos Inulae 2-4, Herba Lophatheri 3.5-5, Cortex Moutan Radicis 2-4, Fructus Jujubae 0.5-2, Semen Ziziphi Spinosae 2-4, Fructus Corni 2-4, Rehmanniae Recens 2-4, Radix Codonopsis 2-4, and Fructus Gardeniae 0.5-2. All herbs of the composition have synergistic effects to tonify liver and supplement qi, nourish blood and tranquilize mind, clear deficient heat, and relieve restlessness.
Description
The present invention relates to a compound preparation of traditional Chinese medicine, in particular to a pharmaceutical composition for the treatment of Menopausal Syndrome and the preparation method thereof.
Menopausal syndrome (MPS) is a series of symptoms caused by dropping levels of estrogen. Because the body cannot adapt quickly during menopause, some women will experience more obvious symptoms, but in generally they do not need special treatments. As for the women having severe symptoms even their daily life and work are severely affected, they need to use traditional Chinese medicine to invigorate kidney and bring back to health. It is generally believed that during the menopause transition years, the changes in family and social environment can increase women’s physical and mental burdens so that they are more prone to experience menopausal syndrome or the existing symptoms would be aggravated. For some mentally unstable women, their menopausal syndrome and even moodiness are more apparent. Although menopausal syndrome is caused by sex physiological changes, the incidence is directly related to the level of personal experience and psychological burden. For the ppsychological sensitive menopausal women, any physical discomfort is likely to cause more psychological changes, which lead to a variety of menopausal symptoms. Therefore, it is important to pay attention to the psychological adjustment.
During the treatment for menopausal syndrome, doctors usually recommend oral medication without implanting and intramuscularly injection. Topical applications are limited to senile virginities, and not suitable for long-term applications. It should be noted that the hormone replacement therapy must be sparingly used with cautions for women who have a history of thrombosis, chronic liver and kidney dysfunction, sex hormone dependent tumors, Pyrrole rhodopsin (PAP) , severe high blood pressure, diabetes, severe varicose veins and smoking or cannot adhere to a long-term follow-up examination. In addition, women who receive hormone replacement therapy should review their cases or visit a clinic every 3 months. When necessary, a gynecological examination and even ultrasound and endometrial biopsy should be received. In breast examination, it must pay attention to lobular hyperplasia or lumps, and monitor the heart, liver, gall bladder, and blood functions.
At present, there are still many disadvantages in hormone replacement therapy which will bring risks to women undergoing such therapy, such as increasing liver load and the probability incidence of endometrial cancer, breast cancer, thrombotic diseases, cholelithiasis and so on. The topical steroids paste that is available now on the market is also have many shortcomings, such as common occurrences of skin ulcers and allergies due to the envelopment therapy of patch preparations. The poor ventilation of the rubber plaster often leads to skin irritation and allergies, and the curing time of gels in the plaster is not easy to control which causes poor adhesion, paste spillages and other problems.
SUMMARY OF THE INVENTION
The present invention provides a pharmaceutical composition for the treatment of menopausal syndrome and its preparation method. The method is believed to be simple, safe and reliable, and suitable for industrial production.
Disclosed is a pharmaceutical composition for the treatment of Menopausal Syndrome, wherein the pharmaceutical composition is consisted of the following herbs in weight parts: 1-3 parts Ramulus Cinnamomi, 0.5-2 parts Rhizoma Zingiberis, 2-4 parts Fructus Schisandrae Chinensis, 2-4 parts Flos Inulae, 3.5-5 parts Herba Lophatheri, 2-4 parts Cortex Moutan Radicis, 0.5-2 parts Fructus Jujubae, 2-4 parts Semen Ziziphi Spinosae, 2-4 parts Fructus Corni, 2-4 parts Radix Rehmanniae Recens, 2-4 parts Radix Codonopsis, and 0.5-2 parts Fructus Gardeniae. The pharmaceutical composition for the treatment of Menopausal Syndrome of the present invention has a high degree of safety and ideal effects for ameliorating Menopausal Syndrome. It is believed that the pharmaceutical composition resolves one or more of the technical problems in prior hormone replacement therapy, such as heavy loads on the liver and increasing probability of the incidence of endometrial cancer, breast cancer, thrombotic diseases and cholelithiasis.
Ramulus Cinnamomi is also known as cassia twig or cinnamon twig. Quality: Pungent, Sweet, Warm. Meridians: Heart, Lung, Bladder. Actions: Induces sweating, warms and unblocks Meridian channels, reinforces yang transforming qi, and suppresses qi from rushing upwards.
Rhizoma Zingiberis is also known as dried ginger. Quality: Pungent, Hot. Meridians: Spleen, Stomach, Kidney, Heart, Lung. Actions: Warms the spleen and stomach, restores devastated yang, warms the lung to transform thin mucus, warms and unblocks channels.
Fructus Schisandrae Chinensis is also known as Chinese magnoliavine fruit. Quality: Sour, Sweet, Warm. Meridians: Lung, Heart, Kidney. Actions: Induces astringency, benefits qi for promoting fluid production, nourishes the kidneys and calms the hearts.
Flos Inulae is also known as inula flower. Quality: Bitter, Pungent, Salty, slightly Warm. Meridians: Lung, Spleen, Stomach, Large Intestine. Actions: descends qi, dissipates phlegm, activates water, arrests vomitting.
Herba Lophatheri is also known as lophatherum herb. Quality: Sweet, Bland, Cold. Meridians: Heart, Stomach, Small Intestine. Actions: clears hear-fire, clears annoyance and quenches thirst, increases urine and removes stone.
Cortex Moutan Radicis is also known as tree peony root bark. Quality: Bitter, Pungent, slightly Cold. Meridians: Heart, Liver, Kidney. Actions: clears heat and cools blood, promotes blood circulation and removes blood stasis.
Fructus Jujubae is also known as Chinese date. Quality: Sweet, Warm. Meridians: Spleed, Stomach, Heart. Actions: invigorates spleen and replenishes qi， nourishes blood and tranquilizes mind.
Semen Ziziphi Spinosae is also known as spine date seed. Quality: Sweet, Sour, Neutral. Meridians: Liver, Bladder, Heart. Actions: invigorates heart and liver， calms heart and tranquilizes mind, astringes sweat, promotes fluid production.
Fructus Corni is also known as asiatic cornelian cherry fruit. Quality: Sour, Astringent, slightly Warm. Meridians: Liver, Kidney. Actions: invigorates liver and kidney， astringes for relieving desertion.
Radix Rehmanniae Recens is also known as unprocessed rehmannia root. Quality: Sweet, Cold. Meridians: Heart, Liver, Kidney. Actions: clears heat and cools blood, nourishes Yin and promotes fluid production.
Radix Codonopsis is also known as tangshen. Quality: Sweet, Neutral. Meridians: Spleen, Lung. Actions: invigorates spleen and benefits lung, nourishes blood and promotes fluid production.
Fructus Gardeniae is also known as cape jasmine fruit. Quality: Bitter, Cold. Meridians: Heart, Lung, Sanjiao. Actions: clears heat-fire and arrests annoyance, clears heat and promotes diuresis, cools blood and removes toxin.
Preferably, the pharmaceutical composition is consisted of the following herbs in weight ratios: 1-2.5 parts Ramulus Cinnamomi, 0.5-1.5 parts Rhizoma Zingiberis, 2-3.5 parts Fructus Schisandrae Chinensis, 2-3.5 parts Flos Inulae, 3.5-4.8 parts Herba Lophatheri, 2-3.5 parts Cortex Moutan Radicis, 0.5-1.5 parts Fructus Jujubae, 2-3.5 parts Semen Ziziphi Spinosae, 2-3.5 parts Fructus Corni, 2-3.5 parts Radix Rehmanniae Recens, 2-3.5 parts Radix Codonopsis, and 0.5-1.5 parts Fructus Gardeniae.
More preferably, the pharmaceutical composition per 30.5g is consisted of the following herbs in weight: Ramulus Cinnamomi 2g, Rhizoma Zingiberis1g, Fructus Schisandrae Chinensis 3g, Flos Inulae 3g, Herba Lophatheri 4.5g, Cortex Moutan Radicis 3g, Fructus Jujubae 1g, Semen Ziziphi Spinosae 3g, Fructus Corni 3g, Radix Rehmanniae Recens 3g, Radix Codonopsis 3g, and Fructus Gardeniae 1g.
Preferably, the pharmaceutical composition for the treatment of menopausal syndrome is manufactured in the form of oral liquid, tablets, capsules, pills, dropping pills, or granules.
A method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
A. All the 12 herbs are blended and boiling decocted by three times and the amount of water added in the decoction process is 7-10 times the total weight of the herbs, wherein the first decoction for 1.5-3h, the second decoction for 1-2h and the third decoction for 0.5-1.5h, when the amount of water added is 7-10 times the total weight of the herbs, the dissolution effects of the herbs will be better during the decoctions, and when the herbs are boiling decocted by three times, the extraction effects of the herbs will be more ideal；
B. The filtrates from the three decoctions are combined and concentrated into an extracting solution with relative density of 1.20-1.25； and
C. The extracting solution is added with ethanol to a concentration of 50-80％, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.12-1.20 which is then dried to obtain the pharmaceutical composition for the treatment of menopausal syndrome, wherein the non-alcohol-soluble substances such as starch, protein, etc. are removed from the decocted extracting solution and forms an extracting solution having a concentration of alcohol by adding ethanol, and then a solid-liquid separation is performed by precipitation at room temperature or preferably lower temperature to improve the concentration and clarity of the alcohol extract and the product quality.
Preferably, the method comprises step D that the pharmaceutical composition is added with starch and homogenized before filling into capsules.
Preferably, the step B further comprises that after the filtrate is combined, the combined filtrate is concentrated into an extract with relative density of 1.20-1.25 at 60 ℃.
Preferably, the step C comprises that the supernatant is concentrated into an extract relative density of 1.12-1.20 at 60 ℃ and spray-dried to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
The present invention is a pharmaceutical composition prepared from traditional medicinal herbs of Ramulus Cinnamomi, Rhizoma Zingiberis, Fructus Schisandrae Chinensis, Flos
Inulae, Herba Lophatheri, Cortex Moutan Radicis, Fructus Jujubae, Semen Ziziphi Spinosae, Fructus Corni, Radix Rehmanniae Recens, Radix Codonopsis, and Fructus Gardeniae. After clinical trials, all the 12 herbs have a synergistic effect with the following results: the pharmaceutical composition can supplement the liver and enriches the qi, nourishes the blood and calms the mind, clears internal heat, and relieves worries, which is especially applicable for women with menopausal syndrome that is induced by deficiency of Yin in their livers and kidneys. It is believed that the pharmaceutical composition for the treatment of menopausal syndrome consisted of the raw materials in such ratios offers a high degree of safety and is effective for improving the symptoms of menopause.
It is believed that the preparation method of the present invention is a simple operation, and is environmentally friendly, economic, efficient, non-toxic, and has the prospect of broad applications.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Example 1
A pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of pillors, in which the pharmaceutical composition is consisted of the following herbs in weight parts: 1 part Ramulus Cinnamomi, 0.5 part Rhizoma Zingiberis, 2 parts Fructus Schisandrae Chinensis, 2 parts Flos Inulae, 3.5 parts Herba Lophatheri, 2 parts Cortex Moutan Radicis, 0.5 parts Fructus Jujubae, 2 parts Semen Ziziphi Spinosae, 2 parts Fructus Corni, 2 parts Radix Rehmanniae Recens, 2 parts Radix Codonopsis, and 0.5 parts Fructus Gardeniae.
The method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
A. All the 12 herbs are blended and boiling decocted by three times and the amount of water added in the decoction process is 7-10 times of the total weight of the herbs, wherein the first decoction for 1.5h, the second decoction for 1.5h and the third decoction for 0.5h；
B. The filtrates from the three decoctions are combined and concentrated into an extracting solution with relative density of 1.20； and
C. The extracting solution is added with ethanol to a concentration of 50％, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.12, and then blended and pelletized to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
Example 2
A pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of oral liquid, in which the pharmaceutical composition is consisted of the following herbs in weight parts: 3 part Ramulus Cinnamomi, 2 part Rhizoma Zingiberis, 4 parts Fructus
Schisandrae Chinensis, 4 parts Flos Inulae, 5 parts Herba Lophatheri, 4 parts Cortex Moutan Radicis, 2 parts Fructus Jujubae, 4 parts Semen Ziziphi Spinosae, 4 parts Fructus Corni, 4 parts Radix Rehmanniae Recens, 4 parts Radix Codonopsis, and 2 parts Fructus Gardeniae.
The method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
A. All the 12 herbs are blended and boiling decocted by three times and the amount of water added in the decoction process is 10 times of the total weight of the herbs, wherein the first decoction for 3h, the second decoction for 2h and the third decoction for 1.5h；
B. The filtrates from the three decoctions are combined and concentrated into an extracting solution with relative density of 1.20 at 60 ℃； and
C. The extracting solution is added with ethanol to a concentration of 80％, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.12 at 60 ℃, and then batched and filled to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
Example 3
A pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of tablets, in which the pharmaceutical composition is consisted of the following herbs in weight parts: 2.5 part Ramulus Cinnamomi, 1.5 part Rhizoma Zingiberis, 3.5 parts Fructus Schisandrae Chinensis, 3.5 parts Flos Inulae, 4.8 parts Herba Lophatheri, 3.5 parts Cortex Moutan Radicis, 1.5 parts Fructus Jujubae, 3.5 parts Semen Ziziphi Spinosae, 3.5 parts Fructus Corni, 3.5 parts Radix Rehmanniae Recens, 3.5 parts Radix Codonopsis, and 1.5 parts Fructus Gardeniae.
The method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
A. All the 12 herbs are blended and boiling decocted by three times and the amount of water added in the decoction process is 8 times of the total weight of the herbs, wherein the first decoction for 2h, the second decoction for 1.5h and the third decoction for 1h；
B. The filtrates from the three decoctions are combined and concentrated into an extracting solution with relative density of 1.23 at 60 ℃； and
C. The extracting solution is added with ethanol to a concentration of 60％, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.15 at 60 ℃, and then spray dried, granulated and compressed to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
Example 4
A pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of capsules, in which the pharmaceutical composition is consisted of the following herbs in weight parts: 2 part Ramulus Cinnamomi, 1 part Rhizoma Zingiberis, 3 parts Fructus
Schisandrae Chinensis, 3 parts Flos Inulae, 4.5 parts Herba Lophatheri, 3 parts Cortex Moutan Radicis, 1 parts Fructus Jujubae, 3 parts Semen Ziziphi Spinosae, 3 parts Fructus Corni, 3 parts Radix Rehmanniae Recens, 3 parts Radix Codonopsis, and 1 part Fructus Gardeniae.
The method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
A. All the 12 herbs are blended and boiling decocted by three times and the amount of water added in the decoction process is 8 times of the total weight of the herbs, wherein the first decoction for 2h, the second decoction for 1.5h and the third decoction for 1h；
B. The filtrates from the three decoctions are combined and concentrated into an extracting solution with relative density of 1.23 at 60 ℃；
C. The extracting solution is added with ethanol to a concentration of 80％, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.15 at 60 ℃, and then spray dried； and
D. Adding starch, blending and encapsulating to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
Example 5
A pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of granules, in which the pharmaceutical composition per 30.5g is consisted of the following herbs in weights: Ramulus Cinnamomi 2g, Rhizoma Zingiberis 1g, Fructus Schisandrae Chinensis 3g, Flos Inulae 3g, Herba Lophatheri 4.5g, Cortex Moutan Radicis 3g, Fructus Jujubae 1g, Semen Ziziphi Spinosae 3g, Fructus Corni 3g, Radix Rehmanniae Recens 3g, Radix Codonopsis 3g, and Fructus Gardeniae 1g.
The method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
A. All the 12 herbs are blended and boiling decocted by three times and the amount of water added in the decoction process is 10 times of the total weight of the herbs, wherein the first decoction for 3h, the second decoction for 2h and the third decoction for 1.5h；
B. The filtrates from the three decoctions are combined and concentrated into an extracting solution with relative density of 1.25 at 60 ℃； and
C. The extracting solution is added with ethanol to a concentration of 80％, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.20 at 60 ℃, and then dried and pelletized to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
.
Example 6
A pharmaceutical composition for treatment of menopausal syndrome is manufactured in form of dripping pills, in which the pharmaceutical composition is consisted of the following herbs in weight parts: 2 part Ramulus Cinnamomi, 1 part Rhizoma Zingiberis, 3 parts Fructus Schisandrae Chinensis, 3 parts Flos Inulae, 4.5 parts Herba Lophatheri, 3 parts Cortex Moutan Radicis, 1 parts Fructus Jujubae, 3 parts Semen Ziziphi Spinosae, 3 parts Fructus Corni, 3 parts Radix Rehmanniae Recens, 3 parts Radix Codonopsis, and 1 part Fructus Gardeniae.
The method for preparing the pharmaceutical composition for the treatment of menopausal syndrome comprises the following steps that:
A. All the 12 herbs are blended and boiling decocted by three times and the amount of water added in the decoction process is 10 times of the total weight of the herbs, wherein the first decoction for 3h, the second decoction for 2h and the third decoction for 1.5h；
B. The filtrates from the three decoctions are combined and concentrated into an extracting solution with relative density of 1.25 at 60 ℃； and
C. The extracting solution is added with ethanol to a concentration of 80％, standing for 24h, and the supernatant is removed and concentrated into an alcohol extract with relative density of 1.20 at 60 ℃, and then batched and made into pills to obtain the pharmaceutical composition for the treatment of menopausal syndrome.
Example 7
1 Drugs and Materials
1.1 Drug testing and reagents: The pharmaceutical compositions for the treatment of menopausal syndrome in form of capsules obtained in Example 4.
1.2 Animals: Female ICR mice provided by the Experimental Animal Center of Zhejiang Province； animal breeding certificate: Zhejiang Medical Animals No. 2001001.
2 Methods and Results
2.1 Sedative, hypnotic and anticonvulsant effects of menopause capsules on normal mice:
52 pcs ICR mice (female, weight 18～22g) are divided into four groups according to drug administration protocols (the pharmaceutical composition capsules for the treatment of menopausal syndrome obtained from Example 4) . A normal control group is fed with water at 0.2ml /10g per day； and the remaining three test groups are administered orally daily doses of the capsules at 2.0g /kg, 1.0 g /kg, and 0.5 g /kg respectively. At 30 minutes after the first eighth dosing, the independent activity numbers of mice are measured within 5 minutes by a Locomotor activity meter (XZ-4 type, from the Drug Institute of Chinese Academy) , and at 30 minutes after the 9th administration, the mice are intraperitoneally injected with 50mg /kg of amyl pentobarbital sodium and their latent sleep time (latency) and sleep time are recorded. At
30 minutes after the 10th dose, the mice are given an intraperitoneal dose of Nikethamide 350mg /kg, and their mortality rate caused by convulsions and seizures is observed. No seizures are calculated as 100 minutes.
Table 1: Sedative and hypnotic effects of menopausal capsules on normal mice (x ± s)
Compared with control group *P <0.05, **P <0.01
The results in Table 1 show that the menopausal capsule significantly inhibits the occurrence of convulsions and seizures caused by Nikethamide in mice. It also significantly delays and reduces the incidence of seizures. The results suggest that in normal mice, the menopausal capsule has obvious sedative and anticonvulsant effects.
2.2 Sedation effects of Menopausal capsule in elderly female mice:
52pcs ICR mice (15-month-old, female, weigh 28～40g) are divided into four groups according to drug administration protocols (the pharmaceutical composition capsules for the treatment of menopausal syndrome obtained from Example 4) . A normal control group is fed with water at 0.2ml /10g per day； and the remaining three test groups are administered orally daily doses of the capsules at 2.0g /kg, 1.0 g /kg, and 0.5 g /kg respectively. All groups of the mice are bred in a conventional manner in the laboratory for 20 days, and then start to be given the menopausal capsules or an equal volume of water. At 30 minutes after administration on the 10th and 20th day, the independent activity numbers of mice are measured within 5 minutes. At 20 minutes after administration on the 21th day, the mice are intra-peritoneally injected with amphetamine at 10mg /kg and the independent activity numbers of mice are measured within 5 minutes after 10 minutes. At the end of the experiments, the mice are sacrificed and their uterus, ovaries and adrenal glands are removed and weighed.
Table 2: Effects of the menopausal capsules on sedation of aged mice (x ± s)
The results in Table 2 show that 10-day menopause capsule administration had no significant effect on spontaneous activity in aged mice, but 20 days of administration of high-dose group showed a significant central inhibition. Large-dose menopause capsules and medium-dose groups had significantly inhibited central amphetamine-induced excitement. Menopause capsules increased adrenal weights, but did not demonstrate stimulating effect on the uterus and ovaries.
2.3 Effects of the menopausal capsule on mice with immune function in Yin deficiency:
76 pcs ICR mice (female, weigh 22～25g) are divided into five groups according to drug administration protocols (the pharmaceutical composition capsules for the treatment of menopausal syndrome obtained from Example 4) . The first group is a control group that is fed with water at 0.2ml /10g per day； the second group is fed daily for consecutive 20 days with thyroxine 0.3 mg and reserpine 0.02mg. The remaining three groups are fed orally with thyroxine 0.3 mg and reserpine 0.02mg daily for 20 consecutive days, and concomitantly a daily dose of menopausal pharmaceutical composition at 2.0g /kg, 1.0 g /kg and 0.5 g /kg respectively. On the14th day, the independent activity numbers of mice are measured. On the 15th day, the mice are given intra peritoneal injection of 5％Sheep erythrocytes at 0.2ml/mouse. On the 21st day, a sample of blood from the femoral artery is collected, the blood serum is separated and the serum hemolysin level determined. The mouse spleen is removed by sterile technique and the lymphocyte transformation and NK cell killing rate are measured.
Table 3: Effect of menopausal capsule on immune function on Yin deficiency mice (x ± s)
Compared with the model group, *P <0.05
The results in Table 3 show that the thyroxine and reserpine induced weight loss and development of fluffy yellow coat in mice and increased their activities. There was a significant Yin deficiency in symptoms. The menopausal capsules significantly increased body weight in mice and improved their appearance. There was also a significant decline in their independent activity nembers. Yin deficient mice showed significant decrease in their humoral and cellular immune functions. The menopause capsule significantly improved cell immune function (lymphocyte transformation) activity but had no significant impact on the specific humoral immune function (HC50) and NK cell activity of immune deficient mice.
2.4 Protective effect of menopausal capsule on Yin deficiency mice
70 pcs ICR mice (female, weigh 22～24g) are divided into five groups according to drug administration protocols (the pharmaceutical composition capsules for the treatment of menopausal syndrome obtained from Example 4) . The first group is a control group that is fed with water 0.2ml /10g per day； the second group is injected every morning with cortisone acetate 1mg /mouse only for 7 days； the remaining three groups are given every morning intramuscular cortisone acetate 1mg /mouse only, while the amount of menopausal capsule administered orally every afternoon are 2.0g /kg, 1.0 g /kg, 0.5 g /kg respectively for 7 days. On the third day the mice are given by an intra peritoneal injection of 20％sheep erythrocytes 0.2ml /mouse. One day after the last test solution administration, femoral arterial blood collected, thymus and spleen weighed； organ coefficient calculation, serum lectin and hemolysin level determined.
Table 4: Effect of menopausal capsule on Yang deficiency mice (x ± s)
The results in Table 4 show that the corticosteroids caused significant Yang deficiency
symptoms in mice including significant weight loss, fluffy fur, reduced activity, hypothermia, unresponsiveness and so on. The menopausal capsule partially restored corticosteroid-induced weight loss and the general state of the animals was relatively good. Glucocorticoid led to a reduction in the weight of the immune organs in mice and significantly decreased their ability to produce specific antibodies. The menopausal capsules significantly restored the weight of the spleen and thymus in mice, their specific immune function was also restored.
In summary, the above descriptions are only examples of the preferred embodiments of the present invention. Any equivalent changes or modifications to the invention within the scope of the present disclosure are also fallen into the scope of the present invention.
The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement of any form of suggestion that such prior art forms part of the common general knowledge.
It will be understood that the term "comprise" and any of its derivatives (eg comprises, comprising) as used in this specification is to be taken to be inclusive of features to which it refers, and is not meant to exclude the presence of any additional features unless otherwise stated or implied.
Claims (10)
- A pharmaceutical composition for the treatment of Menopausal Syndrome, wherein the pharmaceutical composition consists of the following herbs in weight parts:
- The pharmaceutical composition of claim 1, wherein the pharmaceutical composition consists of the following herbs in weight parts:
- The pharmaceutical composition of claim 1, wherein the pharmaceutical composition consists of the following herbs in weight parts:
- The pharmaceutical composition of claim 1, wherein the pharmaceutical composition per 30.5g consists of the following herbs in weights:
- The pharmaceutical composition of any one of claims 1-4, wherein the pharmaceutical composition is in the form of an oral liquid, tablets, capsules, granules, pills, or dripping pills.
- A method for preparing the pharmaceutical composition of any one of claims 1-4, comprising the steps that:A. Blending all the 12 herbs and boiling decocted by three times and the amount of water added in the decoction process is 7-10 times the total weight of the herbs, wherein the first decoction for 1.5-3h, the second decoction for 1-2h and the third decoction for 0.5-1.5h；B. Combining the filtrates from the three decoctions and concentrating into an extracting solution with relative density of 1.20-1.25； andC. Adding ethanol to the extracting solution to a concentration of 50-80％, standing for 24h, removing the supernatant and concentrating into an alcohol extract with relative density of 1.12-1.20, and then drying to obtain the pharmaceutical composition.
- The method according to claim 6, further comprising step D of adding starch to the pharmaceutical composition, homogenizing the mixture and filling into capsules.
- The method according to claim 6, wherein step B comprises combining the filtrates at 60℃ and then concentrating to an extract of relative density of 1.20-1.25.
- The method according to claim 6, wherein step C further comprises concentrating the supernatant at 60℃ to an extract of relative density of 1.12-1.20 and then spray drying to obtain the pharmaceutical composition.
- A method of treating menopausal syndrome, the method comprising administering the pharmaceutical composition of any one of claims 1 to 5.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1718483.9A GB2554010A (en) | 2015-06-10 | 2016-06-03 | Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof |
| HK18104524.7A HK1245097A1 (en) | 2015-06-10 | 2018-04-04 | Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015203092 | 2015-06-10 | ||
| AU2015203092A AU2015203092B1 (en) | 2015-06-10 | 2015-06-10 | Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016197878A1 true WO2016197878A1 (en) | 2016-12-15 |
Family
ID=56306155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2016/084647 WO2016197878A1 (en) | 2015-06-10 | 2016-06-03 | Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN105664108A (en) |
| AU (1) | AU2015203092B1 (en) |
| GB (1) | GB2554010A (en) |
| HK (1) | HK1245097A1 (en) |
| WO (1) | WO2016197878A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108553624A (en) * | 2018-03-27 | 2018-09-21 | 贵州康珠药业有限公司 | It is a kind of to be used to treat plaster of climacteric syndrome and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015203092B1 (en) * | 2015-06-10 | 2016-10-20 | Thisherb Health Pty Ltd | Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306934A (en) * | 2014-10-17 | 2015-01-28 | 浙江施强制药有限公司 | Medicine composition for enhancing immunity and preparation method thereof |
| CN104324346A (en) * | 2014-10-17 | 2015-02-04 | 浙江施强制药有限公司 | Medicine composition with effect of improving sleeping and preparation method thereof |
| CN105664108A (en) * | 2015-06-10 | 2016-06-15 | 浙江施强制药有限公司 | Medical composition for treating climacteric syndrome and preparation thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7482029B2 (en) * | 2005-04-01 | 2009-01-27 | Bionovo, Inc. | Composition for treatment of menopause |
| CN101099838A (en) * | 2007-07-12 | 2008-01-09 | 尹克华 | Traditional Chinese medicine for treating female climacteric syndrome |
| CN102462811A (en) * | 2010-11-05 | 2012-05-23 | 王琴 | Traditional Chinese medicine for treatment of menopausal syndrome |
| CN102743493B (en) * | 2012-06-30 | 2014-02-19 | 江苏省中医药研究院 | Application of kidney-nourishing and liver-cooling recipe in preparation of medicines used for treating climacteric-like symptoms |
| CN103405728B (en) * | 2013-09-06 | 2015-09-09 | 青岛市中心医院 | A kind of Chinese medicine composition for the treatment of climacteric syndrome and preparation method thereof |
| CN103800664A (en) * | 2014-03-18 | 2014-05-21 | 黄淑娟 | Traditional Chinese medicine composition for treating menopausal syndrome |
| CN103861074B (en) * | 2014-03-24 | 2016-05-11 | 李明娥 | One is treated the arthritic Chinese medicine composition of climacteric property |
| CN104436122A (en) * | 2014-11-25 | 2015-03-25 | 成都市飞龙水处理技术研究所 | Orally-taken medicine for treating climacteric syndrome and preparation method thereof |
-
2015
- 2015-06-10 AU AU2015203092A patent/AU2015203092B1/en not_active Ceased
-
2016
- 2016-02-26 CN CN201610108706.9A patent/CN105664108A/en active Pending
- 2016-06-03 GB GB1718483.9A patent/GB2554010A/en active Pending
- 2016-06-03 WO PCT/CN2016/084647 patent/WO2016197878A1/en active Application Filing
-
2018
- 2018-04-04 HK HK18104524.7A patent/HK1245097A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306934A (en) * | 2014-10-17 | 2015-01-28 | 浙江施强制药有限公司 | Medicine composition for enhancing immunity and preparation method thereof |
| CN104324346A (en) * | 2014-10-17 | 2015-02-04 | 浙江施强制药有限公司 | Medicine composition with effect of improving sleeping and preparation method thereof |
| CN105664108A (en) * | 2015-06-10 | 2016-06-15 | 浙江施强制药有限公司 | Medical composition for treating climacteric syndrome and preparation thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108553624A (en) * | 2018-03-27 | 2018-09-21 | 贵州康珠药业有限公司 | It is a kind of to be used to treat plaster of climacteric syndrome and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105664108A (en) | 2016-06-15 |
| GB2554010A (en) | 2018-03-21 |
| AU2015203092B1 (en) | 2016-10-20 |
| HK1245097A1 (en) | 2018-08-24 |
| GB201718483D0 (en) | 2017-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104162094B (en) | A kind of Chinese medicine composition and its pharmaceutical preparation for treating Obesity-type Polycystic Ovary Syndrome | |
| CN104958607A (en) | Traditional Chinese medicine composition for treating burning mouth syndromes of climacteric women and preparation method thereof | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN103099833A (en) | Soft capsule helpful for relieving sports fatigue and delaying aging and preparation method thereof | |
| CN106994141B (en) | Traditional Chinese medicine composition for treating constipation and preparation method thereof | |
| WO2016197878A1 (en) | Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof | |
| KR101600751B1 (en) | Method of preparing oriental medicine composition containing extract of deer antlers for treating infertility in women | |
| CN105126045A (en) | Traditional Chinese medicinal composition for treating climacteric syndrome | |
| CN113599475B (en) | Middle-warming and kidney-tonifying composition for treating polycystic ovarian syndrome and preparation method and application thereof | |
| CN103860773A (en) | Traditional Chinese medicine composition for treating myocardial ischemia and preparation method thereof | |
| CN105362630A (en) | Climacteric syndrome treatment pharmaceutical composition and preparation method thereof | |
| CN105362959A (en) | Qi-tonifying, stasis-dispersing and inflammation-diminishing soup | |
| CN105169149A (en) | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application | |
| CN104173521B (en) | A kind of pharmaceutical composition and its preparation method giving birth to able-bodied sun | |
| CN112022988B (en) | Traditional Chinese medicine composition with effect of preventing and/or treating dysmenorrhea and preparation method and application thereof | |
| CN102233004B (en) | Drug for treating liver diseases | |
| CN114712466B (en) | Medicine with weight-reducing and beautifying effects and preparation method thereof | |
| CN106692690A (en) | Medicine composition for treating juvenile poliosis | |
| CN107441313B (en) | Traditional Chinese medicine composition and medicine for treating ovarian reserve function decline and preparation method thereof | |
| CN105920539A (en) | Medicament for treating foot-and-mouth disease of sheep | |
| CN105362784A (en) | Medicine composition for treating hysteromyoma and preparation method thereof | |
| CN105412244A (en) | Traditional Chinese medicine composition treating gynecological cervicitis | |
| CN117379501A (en) | Application of Zhibaihuang granule in treating yin deficiency type children sexual precocity with obesity | |
| CN114533835A (en) | Medicine with effects of aroma and dispelling wind and promoting diuresis and preparation method thereof | |
| CN103933477B (en) | Chinese medicinal preparation for treating female climacteric syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16806776 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 201718483 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20160603 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 16806776 Country of ref document: EP Kind code of ref document: A1 |